Abstract
The 3 Glu form of osteocalcin (3 Glu-OCN) is increased in serum during low vitamin K intake or oral anticoagulant use (warfarin). Previous reports using circular dichroism show it is less structured than 3 Gla Ca2+-osteocalcin and does not bind strongly to bone mineral. Recent studies have suggested a role for 3 Glu-OCN as a potential regulator of glucose metabolism. A G-protein-coupled receptor, GPRC6a, found in the pancreas and testes was identified as the putative osteocalcin receptor. The purpose of this study is to determine the high-resolution structure of bovine 3 Glu-OCN, using X-ray crystallography, to understand molecular interactions with mineral and the GPRC6a receptor. Diffraction quality crystals of thermally decarboxylated bovine osteocalcin were grown, and the crystal structure was determined to 1.88 Å resolution. The final refined structure contained residues 17–47 and, like 3 Gla Ca2+-OCN, consisted of three α-helices surrounding a hydrophobic core, a C23–C29 disulfide bond between two of the helices, and no bound Ca2+. Thus, the helical structure of 3 Glu-OCN is Ca2+-independent but similar to that of 3 Gla Ca2+-OCN. A reduced level of mineral binding could result from a lower number of Ca2+ coordinating ligands on 3 Glu-OCN. The structure suggests the GPRC6a receptor may respond to helical osteocalcin and will aid in providing molecular mechanistic insight into the role of 3 Glu-OCN in glucose homeostasis.

Osteocalcin, a small, abundant noncollagenous protein synthesized by osteoblasts, contains three γ-carboxyglutamic acid (3 Gla-OCN) residues generated post-translationally in a vitamin K-dependent process.1–3 High-resolution structures from two-dimensional nuclear magnetic resonance (NMR) and X-ray crystallography show that the binding of Ca2+ to the three Gla residues induces a conformational rearrangement to a more globular species, in which these residues occupy positions complementary to the Ca2+ sites presented in the hydroxyapatite crystal.4–7 Consequently, in vivo osteocalcin is predominantly mineral-bound, with a small amount secreted into the circulation.8–13 Several studies have demonstrated a role for osteocalcin in remodeling bone, enhancing mineral deposition, regulating crystal morphology, and increasing bone toughness and fracture resistance.14–20
Recent studies have focused on the unmodified (3 Glu-OCN or 0 Gla-OCN) or partially modified (1 Glu-OCN or 2 Gla-OCN) forms of osteocalcin as potential regulators of glucose metabolism.21,22 Animal- and cell-based studies reported that 3 Glu-OCN or 1 Glu-OCN increases pancreatic β-cell proliferation, insulin secretion, and expression of adiponectin, an insulin-sensitizing hormone produced by adipocytes.21,22 A study in mice suggested that in vivo, binding of insulin to the osteoblast promotes bone resorption where acidification of the bone extracellular matrix (pH 4.5) induces decarboxylation of osteocalcin to the 1 Glu form (13-Glu in mice), resulting in an increased level of insulin secretion and sensitivity.22 Another study showed that intermittent injections of 3 Glu-OCN improved glucose tolerance and insulin sensitivity in the mouse and may prevent the development of type 2 diabetes.23 Recent studies suggest a connection among bone, 3 Glu-OCN, and male fertility.24 A G-protein-coupled receptor (GPCR), GPRC6A, has been identified as the putative osteocalcin receptor.24 A newly published report indicates that 3 Glu-OCN affects brain development and functions via a receptor other than GPRC6A, suggesting there are several receptors for the molecule.25
Both partially modified (1Glu-OCN and 2 Glu-OCN) and unmodified (3 Glu-OCN) forms of osteocalcin are present in humans. A recent study in genetically altered mice suggested that bone resorption by osteoclasts contributes to the partial modification of osteocalcin to the 1 Glu-OCN form and proposed that this may occur in humans, as well.22,26 Older studies demonstrated that bone and serum osteocalcin are partially modified or unmodified as a consequence of suboptimal vitamin K intake in the population.27 Concentrations of partially or unmodified forms of osteocalcin are increased in human serum with vitamin K depletion and decreased with vitamin K supplementation.28,29 Vitamin K deficiency can also be produced with oral anticoagulants (warfarin and coumarin) that act as vitamin K antagonists by inhibiting the epoxide reductase responsible for vitamin K recycling. A study in rats reported a shift in osteocalcin from 3 Gla-OCN to the 3 Glu-OCN form 3 h after warfarin administration.30 It was reported that warfarin is the most widely used anticoagulant in the world, with more than 30 million prescriptions written annually in the United States.31 This indicates that a large percentage of the population is likely to have a significant amount of 3 Glu-OCN and partially modified osteocalcin in their serum.
Despite the reported biological importance of 3 Glu-OCN, little structural information is available. A previous circular dichroism study reported that in the presence of Ca2+, the 3 Glu-OCN molecule contained significantly less α-helical structure than the 3 Gla form.6 Furthermore, the 3 Glu-OCN molecule differed from 3 Gla-OCN in that it did not bind Ca2+,32 was not a mineralization inhibitor,32 and exhibited weakened binding to hydroxyapatite.30,33 Here we report the first high-resolution structure of unmodified bovine osteocalcin (3 Glu-OCN) using X-ray crystallography and compare it to the previously reported structure of the 3 Gla Ca2+-OCN. The structural information reported here may help explain previously reported observations and provides mechanistic insights into the interaction of both 3 Glu-OCN and 3 Gla Ca2+-OCN with physiologically important cell surface receptors.
METHODS
Bovine osteocalcin was purified from bovine bone powder as previously described.34 The purity of the protein was determined by polyacrylamide gel electrophoresis, reverse-phase high-performance liquid chromatography, and amino acid analysis. Dry bovine 3 Glaosteocalin was decarboxylated as previously described.32 Briefly, 2–5 mg of dry bovine 3 Gla protein was dissolved in 0.05 M HCl and freeze-dried in a vacuum reaction tube. Decarboxylation was accomplished by heating the dried protein in vacuo at 110°C for 3.0 h.32 For crystallization studies, the lyophilized 3 Glu protein was resuspended in 20 mM NaCl and 10 mM CaCl2 (pH 7.0) at a concentration of 13.3 mg/mL.
Protein Crystallization
Diffraction quality crystals were grown using the sitting drop vapor diffusion method by mixing 1 μL of protein and 1 μL of reservoir solution and equilibrating samples against the corresponding reservoir solution. The reservoir solution contained 2.5 M ammonium sulfate and 0.1 M Bis-Tris propane (pH 7.0). Crystals reached maximal size in 4 weeks.
Collection of X-ray Diffraction Data and Crystallographic Refinement
Crystals of 3 Glu-OCN with dimensions 0.2 mm × 0.2 mm × 0.2 mm were supplemented with 0.8 M lithium sulfate as a cryoprotectant and flash-cooled in liquid nitrogen. Diffraction data were collected on a Quantum 315 CCD detector (Area Detector Systems Corp.) with 1.08 Å wavelength radiation on the X29A beamline [National Synchrotron Light Source (NSLS), Brookhaven National Laboratory, Upton, NY]. Intensities were integrated using HKL2000 and reduced to amplitudes using SCALE-PACK2MTZ (see Table 1 for statistics).35,36 The structure was determined by molecular replacement using PHASER.37 Model building and refinement were performed with REFMAC and COOT.36,38 The quality of the final structure was verified with composite omit maps, and the stereochemistry was checked with MOLPROBITY.39 The LSQKAB and SSM algorithms were used for structural superimpositions.36,40 Figures were prepared using PyMOL (Schrödinger, LLC).
Table 1.
Data Collection and Refinement Statistics for 3 Glu-OCN
| Data Collection | |
| beamline | NSLS-X29A |
| wavelength (Å) | 1.08 |
| resolution limits (Å) | 20–1.88 |
| no. of observed reflections | 39344 |
| no. of unique reflections | 5668 |
| completeness (%) | 99.9 (98.9)a |
| Rmergeb | 0.063 (0.663)a |
| Refinement | |
| no. of protein non-hydrogen atoms | 525 |
| no. of water molecules | 30 |
| Rcrystc | 0.174 (0.176)a |
| Rfreec | 0.245 (0.290)a |
| average B factor (Å2) | 41.1 |
| rmsd from ideality | |
| bond lengths (Å) | 0.010 |
| bond angles (deg) | 1.30 |
| torsion angles (deg) | 22.2 |
| Ramachandran plot (%) | |
| core | 100.0 |
| allowed | 0.0 |
| generous | 0.0 |
Values in parentheses indicate statistics for the high-resolution bin.
Rmerge = ΣΣj|Ij(hkl) − 〈I(hkl)〉|/ΣΣj|〈I(hkl)〉|, where Ij is the intensity measurement for reflection j and 〈I〉 is the mean intensity over j reflections.
Rcryst/Rfree = Σ∥Fo(hkl)| − |Fc(hkl)∥/Σ|Fo(hkl)|, where Fo and Fc are observed and calculated structure factors, respectively. No σ cutoff was applied. Five percent of the reflections were excluded from refinement and used to calculate Rfree.
RESULTS
Crystal Structure of 3 Glu-OCN
Diffraction from the 3 Glu-OCN crystals was consistent with space group P41with two 3 Glu-OCN molecules per asymmetric unit and the following unit cell dimensions: a = b = 42.76 Å, c = 37.99 Å, and α = β = γ = 90°. The structure of 3 Glu-OCN was determined using the molecular replacement method (PHASER37) with the structure of porcine osteocalcin [Protein Data Bank (PDB) entry 4MZZ] as a starting model. The two chains in the asymmetric unit are related by a local 2-fold axis, but according to PISA analysis within COOT,38 the limited subunit interface is not predicted to support dimer formation in solution. The two chains are very similar (rmsd of 0.31 Å, among all Cα atoms), with only some side chain deviations (see Figure 1B). The final refined structure contains residues Glu 17–Gly 47 in chain A, Glu 17– Pro 48 in chain B, and 30 water molecules. Residues 1–16 and 49 are not represented in the refined electron density map, consistent with the unstructured, unconstrained N-terminal region (residues 1–15) previously reported for the structure of bovine 3 Gla Ca2+-OCN determined by solution NMR.4 The structure of 3 Glu-OCN (Figure 1) consists of three α-helices (H1–H3) with only one residue, Asn 26, outside the α-helical region of the Ramachandran plot. The asparagine side chains at the N-terminus of a helix are known to be stabilizing as a consequence of hydrogen bonds formed with exposed main chain amides. This may be the case in our structure in chain A, but in chain B, the orientation of Asn 26 is distorted by crystal contacts. The possible stabilizing interaction of the Asn 26 side chain is shown in Figure 1A. Helices 1 and 2 cross at an angle of aproximately 120° and are linked by a disulfide bond between Cys 23 and Cys 29. The hydrophobic core of the 3 Glu-OCN molecule is located among the three helices as shown in Figure 1A. The three functionally important Glu side chains extend from helix 1 (H1) and are fully solvent-exposed on a common face of the helix, consistent with direct contacts that would support mineral binding.
Figure 1.

(A) Bovine 3 Glu-OCN structure showing the relative orientation of the main helices (H1–H3) as well as the disulfide bridge (C23–C29, yellow bond) and the hydrophobic side chain interactions within the hydrophobic core (salmon). The Asn 26 residue is shown capping the N-terminus of helix 2. The structural comparison between bovine 3 Glu-OCN (B) [where the Glu side chains are colored cyan (thin bonds, in chain B)] and porcine 3 Gla Ca2+-OCN (C, PDB entry 1Q8H). The calcium ions are shown as green spheres, and coordinating ligands were determined in the previously published X-ray crystal structure.7
The structures of 3 Glu-OCN and porcine 3 Gla Ca2+-OCN (previously determined by X-ray crystallography7) are very similar (Figure 1B,C), with an amino acid sequence identity of 97% in the structured regions of the molecules (residues 17–47) and an rmsd of 0.61 Å (among all Cα atoms). Important differences between the two species are the fact that the 3 Glu-OCN molecule does not show bound Ca2+ and the fact that the 3 Glu-OCN molecule is monomeric at protein concentrations used for crystallography. In contrast, 3 Gla-OCN possesses additional COOH groups as a consequence of the post-translational modification of the side chains of E17, E21, and E24, resulting in Gla residues (X) that coordinate Ca2+ in solution and in the mineral phase.7,32 NMR and crystallography studies reported that 3 Gla Ca2+-OCN formed a Ca2+-dependent dimer, with the dimer interface at the Ca2+ binding sites (Kd for dimerization of 160–200 μM).4,7 However, the in vivo osteocalcin concentrations are much lower, in the nanomolar range,11 suggesting that the monomer is the physiologically relevant oligomeric state. The number and positions of the Ca2+ ions in Figure 1C are those reported in the dimer interface of the porcine Ca2+-OCN X-ray structure7 and also the predicted Ca2+ binding sites for the monomer interacting with the bone crystal surface.7 This previous study reported three tight and two weaker Ca2+ binding sites.7 The important difference between the two structures is that apo 3 Glu-OCN adopts a highly helical structure that is independent of Ca2+, whereas past studies have shown apo 3 Gla-OCN is an unstructured random coil, requiring millimolar levels of Ca2+ to adopt the helical structure.5,6
DISCUSSION
We have determined the first high-resolution structure of bovine 3 Glu-OCN using X-ray crystallography. There is considerable sequence homology among all species of osteocalcin and several conserved regions, including the Glu helix (H1), as well as the two other helical regions of the molecule (H2 and H3). Bovine osteocalcin shares 97% sequence identity with human osteocalcin, as well as a porcine ortholog, in the structured portion of the molecule (residues 17–47). Thus, the structure reported here is likely to be representative of 3 Glu-OCN in all of these species. Murine osteocalcin has a sequence less identical to that of the bovine form (61%); however, secondary structure analysis programs and homology modeling predict the same helical regions in this protein.41 Conservation of key hydrophobic residues also suggests the presence of a hydrophobic core and a similar structure in murine 3 Glu-OCN.
Previous structural studies of 3 Glu-OCN were limited to circular dichroism (CD) spectra,6 which predicted a rather unstructured, less helical (18–26%) molecule as compared to 3 Gla Ca2+-OCN (38%).6 These values contrast the significantly greater helical contents observed in our crystal structure of 3 Glu-OCN in this study (57%) or in the crystal structure of 3 Gla Ca2+-OCN (57%) reported previously.7 For a number of helical proteins (myoglobin, hemoglobin, lysozyme, calmodulin, etc.), the helical content predicted by CD is significantly lower than that exhibited by X-ray crystallography or Fourier transform infrared solution spectroscopy.42 Inaccuracies in CD measurements can arise from the presence of scattering particles or protein concentrations that are too high or too low. Also, data collected in buffers at physiological ionic strength (0.150 M NaCl) can show a signal fluctuation around 190 nm due to Cl− ions that compromise the accuracy of the protein secondary structural prediction.42 Variability and overlap in the positions of the protein absorption bands as well as limited reference data reflect additional challenges for the empirical analysis of CD data.42 It is likely that these factors contribute to the discrepancy in secondary structure content determined by CD spectroscopic and crystallographic methods.
The structure of 3 Glu-OCN is very similar to that of 3 Gla Ca2+-OCN. The requirement for millimolar concentrations of Ca2+, or other divalent metal cations, to induce the conformational change in 3 Gla-OCN is most likely related to the need to neutralize the electrostatic repulsion in this region before the molecule can properly fold into a helix. The 3 Glu molecule has a significantly lower negative charge, and glutamic acid has a strong propensity to adopt a helical conformation, supporting a well-folded and compact structure in the absence of Ca2+. The structure of 2 Gla Ca2+-OCN (Glu 13, mouse; Glu 17, bovine and human) has not yet been reported but has a sequence similar to that of 3 Gla Ca2+-OCN except one fewer negative charge. The Ca2+ dependence of 2 Gla-OCN is unknown but may lie somewhere between the 3 Glu- and 3 Gla Ca2+-OCN molecules.
Previous reports have shown that unmodified osteocalcin (3 Glu OCN) does not bind Ca2+,32 is not a mineralization inhibitor,32 and exhibits a reduced level of binding to hydroxyapatite and bone.30,33 Because the tertiary structures of 3 Gla Ca2+-OCN and 3 Glu-OCN are similar, the differences in Ca2+ binding properties in solution and in the mineral phase are most likely due to the reduced number of Ca2+-coordinating ligands on 3 Glu-OCN. The Ca2+ ion requires six coordinating ligands that can be donated from the protein and H2O molecules. 3 Gla-OCN would have more Ca2+ ligands contributed from carboxyl groups on the protein, rather than from H2O molecules, leading to stronger Ca2+ binding in both the solution and mineral phases. This would explain why 3 Glu-OCN is not an effective inhibitor of hydroxyapatite crystallization from metastable solutions of Ca2+ and HPO42− 32 and does not bind as well to hydroxyapatite.30,33
Recent studies have suggested that the unmodified form, 3 Glu-OCN, and partially modified form of osteocalcin, 1 Glu-OCN, are bone-derived multifunctional hormones.21,22,24 In vivo studies in mice and in vitro studies in cells reported that the 3 Glu-OCN and 1 Glu-OCN molecules increased the level of pancreatic β-cell proliferation, insulin secretion, insulin sensitivity, and energy expenditure.21,22 Data from cellular and genetic experiments also suggested that 3 Glu-OCN plays a role in male fertility by promoting the synthesis of testosterone by Leydig cells in the testes.24 Further experiments identified the receptor for 3 Glu-OCN as a G-protein-coupled receptor, GPRC6A, expressed in Leydig cells in the testes.24 A later study provided evidence that GPRC6A was the receptor for 3 Glu-OCN in mouse pancreatic β cells and in the mouse pancreas in vivo.43
GPRC6A belongs to the C family of G-protein-coupled receptors that mediate intracellular responses to diverse extracellular stimuli.44 This receptor is present in most tissues except intestines and parathyroid gland and may regulate multiple processes.45–47 Neither the structure of GPRC6A nor the molecular mechanism for osteocalcin binding has been reported. However, an in vitro study investigating the ligand specificity for GPRC6A stimulation suggests the receptor may respond to osteocalcin in a helical conformation.47 It was shown that 3 Gla-OCN did not stimulate GPRC6A at low Ca2+ concentrations (<1 mM) but exhibited a dose-dependent stimulation at Ca2+ concentrations from 1 to 5 mM.47 The maximal stimulation occurring at 5 mM Ca2+ is consistent with the Ca2+ concentration shown to induce the maximal helical conformational change in 3 Gla-OCN.5,6 This is further supported by the ability of 3 Gla-OCN and millimolar concentrations of either Sr2+ or Mg2+ (divalent cations shown to induce α-helical structure in 3 Gla-OCN) to stimulate GPRC6A.6,47 The apo form of 3 Gla-OCN is an unstructured random coil that becomes increasingly helical upon Ca2+ or divalent metal ion complexation.5,6 The three Gla residues bind Ca2+ rather weakly with Kd values in the millimolar range, and an NMR titration showed that three Ca2+ ions per molecule are needed to achieve the maximal structural change.4,48 Thus, at Ca2+ concentrations of 0–1 mM, a large fraction of the molecules would be only partially complexed with Ca2+ and significantly less helical than at 5 mM Ca2+ as shown by CD titrations.5,6
Further support for a role of helical osteocalcin in the stimulation of GPRC6A comes from the structure of 3 Glu-OCN reported in this study, which exhibits the same α-helical conformation as 3 Gla Ca2+-OCN. The 3 Glu-OCN molecule was reported to stimulate GPRC6A in pancreatic and testes cells.24,43 Several studies have shown that 3 Glu-OCN is a molecule involved in insulin signaling, whereas 3 Gla-OCN is not effective.21,22 If GPRC6A responds to helical osteocalcin, then in vivo in serum or in media with Ca2+ concentrations of 1 mM, the receptor would be more responsive to helical 3 Glu-OCN as opposed to a less structured 3 Gla Ca2+-OCN. It is possible that 3 Glu-OCN may be involved in cell receptor interactions where helical osteocalcin is required and the Ca2+ concentration is low, while 3 Gla-OCN affects bone and mineral crystal properties through its ability to bind divalent metal cations in both mineral and solution. The structure reported in this study may aid in the development of a molecular mechanism for the interaction of 3 Glu-OCN and 3 Gla Ca2+-OCN with cell surface receptors and may shed light on the role of unmodified 3 Glu-OCN in glucose homeostasis.
Acknowledgments
We thank Dr. Caren Gundberg who generously provided the bovine 3 Glu-OCN sample used in this study, Rafael Toro for his assistance with crystallization, and the NSLS X29 beamline staff for their assistance with diffraction data collection.
Funding: The funding for this study was provided by National Institutes of Health (NIH) Grant ES 009032 to T.L.D., NIH Grant GM094662 to S.C.A., and a grant from the Albert Einstein Cancer Center (CA013330) to S.C.A.
ABBREVIATIONS
- Gla
γ-carboxyglutamic acid
- Glu
glutamic acid
- rmsd
root-mean-square deviation
Footnotes
Notes
The authors declare no competing financial interest.
References
- 1.Hauschka PV, Lian JB, Gallop PM. Direct identification of the calcium binding amino acid, γ-carboxyglutamate in mineralized tissue. Proc Natl Acad Sci USA. 1975;72:3925–3929. doi: 10.1073/pnas.72.10.3925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Price PA, Otsuka AS, Poser JW, Kristaponis J, Raman N. Characterization of a γ-carboxyglutamic acid containing protein from bone. Proc Natl Acad Sci USA. 1976;73:1447–1451. doi: 10.1073/pnas.73.5.1447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Berkner KL. The vitamin K-dependent carboxylase. Annu Rev Nutr. 2005;25:127–149. doi: 10.1146/annurev.nutr.25.050304.092713. [DOI] [PubMed] [Google Scholar]
- 4.Dowd T, Rosen J, Li L, Gundberg C. The three-dimensional structure of bovine calcium ion-bound osteocalcin using 1H NMR spectroscopy. Biochemistry. 2003;42:7769–7779. doi: 10.1021/bi034470s. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Dowd T, Rosen J, Mints L, Gundberg C. The effect of Pb2+ on the structure and hydroxyapatite binding properties of osteocalcin. Biochim Biophys Acta. 2001;1535:153–163. doi: 10.1016/s0925-4439(00)00094-6. [DOI] [PubMed] [Google Scholar]
- 6.Hauschka PV, Carr SA. Calcium-dependent α-helical structure in osteocalcin. Biochemistry. 1982;21:2538–2547. doi: 10.1021/bi00539a038. [DOI] [PubMed] [Google Scholar]
- 7.Hoang QQ, Sicheri F, Howard AJ, Yang DSC. Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature. 2003;425:977–980. doi: 10.1038/nature02079. [DOI] [PubMed] [Google Scholar]
- 8.Boivin G, Morel G, Lian JB, Anthoine-Terrier C, Dubois PM, Meunier PJ. Localization of endogenous osteocalcin in neonatal rat bone and its absence in articular cartilage: Effect of warfarin treatment. Virchows Arch A: Pathol Anat Histopathol. 1990;417:505–512. doi: 10.1007/BF01625731. [DOI] [PubMed] [Google Scholar]
- 9.Hauschka PV, Reid ML. Timed appearance of a calcium-binding protein containing γ-carboxyglutamic acid in developing chick bone. Dev Biol. 1978;65:426–434. doi: 10.1016/0012-1606(78)90038-6. [DOI] [PubMed] [Google Scholar]
- 10.Price PA, Lothringer JW, Baukol SA, Reddi AH. Developmental appearance of the vitamin K-dependent protein of bone during calcification. Analysis of mineralizing tissues in human, calf, and rat. J Biol Chem. 1981;256:3781–3784. [PubMed] [Google Scholar]
- 11.Hauschka PV, Lian JB, Cole DEC, Gundberg CM. Osteocalcin and Matrix Gla proteins: Vitamin K-Dependent Proteins in Bone. Physiol Rev. 1989;69:990–1047. doi: 10.1152/physrev.1989.69.3.990. [DOI] [PubMed] [Google Scholar]
- 12.McKee MD, Farach-Carson MC, Butler WT, Hauschka PV, Nanci A. Ultrastructural immunolocalization of noncollagenous, (osteopontin and osteocalcin) and plasma (albumin and α2 HS-glycoprotein) proteins in rat bone. J Bone Miner Res. 1993;8:485–496. doi: 10.1002/jbmr.5650080413. [DOI] [PubMed] [Google Scholar]
- 13.Owen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, Kennedy MB, Pockwinse S, Lian JB, Stein GS. Progressive development of the rat osteoblast phenotype in vitro: Reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol. 1990;143:420–430. doi: 10.1002/jcp.1041430304. [DOI] [PubMed] [Google Scholar]
- 14.Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J. 1996;317:59. doi: 10.1042/bj3170059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Romberg RW, Werness PG, Riggs BL, Mann KG. Inhibition of hydroxyapatite-crystal growth by bone-specific and other calcium-binding proteins. Biochemistry. 1986;25:1176–1180. doi: 10.1021/bi00353a035. [DOI] [PubMed] [Google Scholar]
- 16.Lian J, Tassinari M, Glowacki J. Resorption of implanted bone prepared from normal and warfarin-treated rats. J Clin Invest. 1984;73:1223. doi: 10.1172/JCI111308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Liggett WH, Lian JB, Greenberger JS, Glowacki J. Osteocalcin promotes differentiation of osteoclast progenitors from murine long-term bone marrow cultures. J Cell Biochem. 2004;55:190–199. doi: 10.1002/jcb.240550206. [DOI] [PubMed] [Google Scholar]
- 18.Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G. Increased bone formation in osteocalcin-deficient mice. Nature. 1996;382:448–452. doi: 10.1038/382448a0. [DOI] [PubMed] [Google Scholar]
- 19.Boskey AL, Gadaleta S, Gundberg C, Doty SB, Ducy P, Karsenty G. Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone. 1998;23:187–196. doi: 10.1016/s8756-3282(98)00092-1. [DOI] [PubMed] [Google Scholar]
- 20.Poundarik AA, Diab T, Sroga GE, Ural A, Boskey AL, Gundberg CM, Vashishth D. Dilatational band formation in bone. Proc Natl Acad Sci USA. 2012;109:19178–19183. doi: 10.1073/pnas.1201513109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–469. doi: 10.1016/j.cell.2007.05.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142:296–308. doi: 10.1016/j.cell.2010.06.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50:568–575. doi: 10.1016/j.bone.2011.04.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, Karsenty G. Endocrine Regulation of Male Fertility by the Skeleton. Cell. 2011;144:796–809. doi: 10.1016/j.cell.2011.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Oury F, Khrimian L, Denny CA, Gardin A, Chamouni A, Goeden N, Huang YY, Lee H, Srinivas P, Gao XB, Suyama S, Langer T, Mann JJ, Horvath TL, Bonnin A, Karsenty G. Maternal and offspring pools of osteocalcin influence brain development and functions. Cell. 2013;155:228–241. doi: 10.1016/j.cell.2013.08.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Lacombe J, Karsenty G, Mathieu F. In vivo analysis of the contribution of bone resorption to the control of glucose metabolism in mice. Mol Metab. 2013 doi: 10.1016/j.mol-met.2013.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: Marker or mediator? Nat Rev Endocrinol. 2013;9:43–55. doi: 10.1038/nrendo.2012.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Binkley NC, Krueger DC, Kawahara TN, Engelke JA, Chappell RJ, Suttie JW. A high phylloquinone intake is required to achieve maximal osteocalcin γ-carboxylation. Am J Clin Nutr. 2002;76:1055–1060. doi: 10.1093/ajcn/76.5.1055. [DOI] [PubMed] [Google Scholar]
- 29.Sokoll LJ, Booth SL, O’Brien ME, Davidson KW, Tsaioun KI, Sadowski JA. Changes in serum osteocalcin, plasma phylloquinone, and urinary γ-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr. 1997;65:779–784. doi: 10.1093/ajcn/65.3.779. [DOI] [PubMed] [Google Scholar]
- 30.Price PA, Williamson MK, Lothringer JW. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981;256:12760–12766. [PubMed] [Google Scholar]
- 31.Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753–764. doi: 10.1056/NEJMoa0809329. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Poser JW, Price PA. A method for decarboxylation of γ-carboxyglutamic acid in proteins. Properties of the decarboxylated γ-carboxyglutamic acid protein from calf bone. J Biol Chem. 1979;254:431–436. [PubMed] [Google Scholar]
- 33.Price PA, Epstein DJ, Lothringer JW, Nishimoto SK, Poser JW, Williamson MK. In: Vitamin K Metabolism and Vitamin K-dependent Proteins. Suttie JW, editor. University Park Press; Baltimore: 1979. pp. 219–226. [Google Scholar]
- 34.Gundberg CM, Hauschka PV, Lian JB, Gallop PM. Osteocalcin: Isolation, characterization, and detection. Methods Enzymol. 1984;107:516–544. doi: 10.1016/0076-6879(84)07036-1. [DOI] [PubMed] [Google Scholar]
- 35.Otwinowski Z, Minor W. Processing of X-ray diffraction data. Methods Enzymol. 1997;276:307–326. doi: 10.1016/S0076-6879(97)76066-X. [DOI] [PubMed] [Google Scholar]
- 36.Bailey S. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. 1994;D50:760–763. doi: 10.1107/S0907444994003112. [DOI] [PubMed] [Google Scholar]
- 37.Storoni LC, McCoy AJ, Read RJ. Likelihood-enhanced fast rotation functions. Acta Crystallogr. 2004;D60:432–438. doi: 10.1107/S0907444903028956. [DOI] [PubMed] [Google Scholar]
- 38.Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. 2004;D60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]
- 39.Chen BV, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr. 2010;D66:12–21. doi: 10.1107/S0907444909042073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. 2004;D60:2256–2268. doi: 10.1107/S0907444904026460. [DOI] [PubMed] [Google Scholar]
- 41.Rost B, Yachdav G, Liu J. The PredictProtein server. Nucleic Acids Res. 2004;32:W321–W326. doi: 10.1093/nar/gkh377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Lin K, Yang H, Gao Z, Li F, Yu S. Overestimated accuracy of circular dichroism in determining protein secondary structure. Eur Biophys J. 2013:1–7. doi: 10.1007/s00249-013-0896-y. [DOI] [PubMed] [Google Scholar]
- 43.Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J Bone Miner Res. 2011;26:1680–1683. doi: 10.1002/jbmr.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Brauner-Osborne H, Wellendorph P, Jensen AA. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr Drug Targets. 2007;8:169–184. doi: 10.2174/138945007779315614. [DOI] [PubMed] [Google Scholar]
- 45.Wellendorph P, Brauner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene. 2004;335:37–46. doi: 10.1016/j.gene.2004.03.003. [DOI] [PubMed] [Google Scholar]
- 46.Kuang D, Yao Y, Lam J, Tsushima RG, Hampson DR. Cloning and characterization of a family C orphan G-protein coupled receptor. J Neurochem. 2005;93:383–391. doi: 10.1111/j.1471-4159.2005.03025.x. [DOI] [PubMed] [Google Scholar]
- 47.Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, Fontilla-Poole M, Mays RW, Brunden KR, Harrington JJ, Quarles LD. Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem. 2005;280:40201–40209. doi: 10.1074/jbc.M505186200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Price PA, Otsuka AS, Poser JW. In: Calcium Binding Proteins and Calcium Function. Wasserman RH, editor. Elsevier; Amsterdam: 1977. pp. 338–347. [Google Scholar]
